帕博利珠单抗联合化疗用于PD-L1肿瘤比例评分小于1%的转移性非小细胞肺癌:五年随访结局的汇总分析
该探索性汇总分析纳入KEYNOTE-189与KEYNOTE-407全球及扩展研究中的442例PD-L1 TPS小于1%的初治转移性NSCLC患者(帕博利珠单抗联合化疗255例,化疗187例),中位随访60.7个月。帕博利珠单抗联合化疗较化疗改善总生存(HR 0.64,95%CI 0.51‒0.79)和无进展生存(HR 0.66,95%CI 0.54‒0.81),5年总生存率分别为12.5%与9.3%。
要点
- PD-L1 TPS小于1%的初治转移性NSCLC中,帕博利珠单抗联合化疗较化疗改善总生存(HR 0.64)。
- 5年总生存率帕博利珠单抗联合化疗组12.5%,化疗组9.3%。
- 3至5级治疗相关不良事件发生率帕博利珠单抗联合化疗组59.1%,化疗组61.3%。
核心结论
- 约5年随访时,帕博利珠单抗联合化疗较单纯化疗在PD-L1 TPS小于1%的初治转移性NSCLC患者中提供有临床意义且持久的生存改善。
- 这些结果继续支持帕博利珠单抗联合化疗作为该患者群体的标准治疗。
研究设计与样本
- 探索性汇总分析,纳入KEYNOTE-189全球研究(NCT02578680)与日本扩展研究(NCT03950674)中无EGFR或ALK改变的转移性非鳞状NSCLC患者,以及KEYNOTE-407全球研究(NCT02775435)与中国扩展研究(NCT03875092)中转移性鳞状NSCLC患者的个体患者数据。
- KEYNOTE-189中患者接受帕博利珠单抗或安慰剂联合培美曲塞及顺铂或卡铂;KEYNOTE-407中患者接受帕博利珠单抗或安慰剂联合卡铂及紫杉醇或白蛋白结合型紫杉醇。
- PD-L1 TPS采用PD-L1 IHC 22C3 pharmDx(Agilent Technologies,Carpinteria,CA)集中评估。
- 共纳入442例患者(帕博利珠单抗联合化疗组255例,化疗组187例),中位随访60.7个月(范围49.9‒72.0个月)。
主要发现
- 帕博利珠单抗联合化疗较化疗改善总生存(HR 0.64;95%CI 0.51‒0.79)。
- 帕博利珠单抗联合化疗较化疗改善无进展生存(HR 0.66;95%CI 0.54‒0.81)。
- 5年总生存率(95%CI)帕博利珠单抗联合化疗组为12.5%(8.6%‒17.3%),化疗组为9.3%(5.6%‒14.1%)。
- 3至5级治疗相关不良事件发生率帕博利珠单抗联合化疗组为59.1%,化疗组为61.3%。
关键数值与推荐
- PD-L1 TPS小于1%为纳入条件,采用PD-L1 IHC 22C3 pharmDx集中评估。
- 总生存HR 0.64(95%CI 0.51‒0.79),帕博利珠单抗联合化疗组255例 vs 化疗组187例。
- 无进展生存HR 0.66(95%CI 0.54‒0.81),帕博利珠单抗联合化疗组255例 vs 化疗组187例。
- 5年总生存率帕博利珠单抗联合化疗组12.5%(95%CI 8.6%‒17.3%)vs 化疗组9.3%(95%CI 5.6%‒14.1%)。
临床怎么用
- 作者结论认为这些结果继续支持帕博利珠单抗联合化疗作为PD-L1 TPS小于1%的初治转移性NSCLC患者的标准治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic NSCLC with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) less than 1% enrolled in phase III studies of pembrolizumab plus chemotherapy versus placebo plus chemotherapy. METHODS: This exploratory pooled analysis included individual patient data from the KEYNOTE-189 global (NCT02578680) and Japan extension (NCT03950674) studies of metastatic nonsquamous NSCLC without EGFR or ALK alterations and the KEYNOTE-407 global (NCT02775435) and People's Republic of China extension (NCT03875092) studies of metastatic squamous NSCLC. Patients received pembrolizumab or placebo plus pemetrexed and cisplatin or carboplatin in KEYNOTE-189 and pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in KEYNOTE-407. PD-L1 TPS was centrally assessed using PD-L1 IHC 22C3 pharmDx (Agilent Technologies, Carpinteria, CA). RESULTS: Overall, 442 patients were included in this analysis (pembrolizumab plus chemotherapy, n = 255; chemotherapy, n = 187). The median follow-up was 60.7 (range, 49.9‒72.0) months. Pembrolizumab plus chemotherapy improved overall survival (hazard ratio, 0.64; 95% confidence interval [CI]: 0.51‒0.79) and progression-free survival (hazard ratio, 0.66; 95% CI: 0.54‒0.81) versus chemotherapy. The 5-year overall survival rates (95% CI) were 12.5% (8.6%‒17.3%) versus 9.3% (5.6%‒14.1%). Grades 3 to 5 treatment-related adverse events occurred in 59.1% of patients for pembrolizumab plus chemotherapy and 61.3% for chemotherapy. CONCLUSION: With approximately 5 years of follow-up, pembrolizumab plus chemotherapy provided clinically meaningful and durable improvements in survival outcomes versus chemotherapy alone in patients with previously untreated metastatic NSCLC with PD-L1 TPS less than 1%. These results continue to support pembrolizumab plus chemotherapy as a standard of care in this patient population. CLINICALTRIALS: gov, NCT02578680 (KEYNOTE-189 global), NCT03950674 (KEYNOTE-189 Japan extension), NCT02775435 (KEYNOTE-407 global), NCT03875092 (KEYNOTE-407 People's Republic of China extension).
引用
- Gadgeel SM, Rodríguez-Abreu D, Halmos B, et al. Pembrolizumab Plus Chemotherapy for Metastatic NSCLC With Programmed Cell Death Ligand 1 Tumor Proportion Score Less Than 1%: Pooled Analysis of Outcomes After Five Years of Follow-Up. J Thorac Oncol. 2024. PMID: 38642841. doi:10.1016/j.jtho.2024.04.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。